Calidi Biotherapeutics has the opportunity to be first-to-market with patented proprietary approaches that have the potential to revolutionize the way that cancer is treated. The safety of Calidi’s proprietary treatment protocol, combining stem cells with oncolytic viruses, was established during the recently completed Phase I clinical trial with 25 patients. Calidi Biotherapeutics is currently seeking FDA approval for a Phase II clinical trial.
Calidi‘s proprietary engineered oncolytic viruses can be selectively programmed in a variety of ways, including: i) imaging to diagnose cancer, ii) delivering additional therapeutic agents, and iii) targeting cancer stem cells responsible for the cancer recurrence. There are multiple product lines in development to deliver a diverse range of anti-cancer and immune-modulatory agents.